Table 3.
Randomized phase III trial of sunitinib compared to interferon-α in advanced renal cell cancer patients not having prior systemic therapy [Motzer et al. 2009, 2007b].
Treatment | PFS | p value | OS | p value |
---|---|---|---|---|
Sunitinib | 11 | <0.001 | 26.4 | 0.051 |
Interferon-α | 5 | 21.8 |
OS, overall survival; PFS, progression-free survival.